Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 325
- Registration Number
- NCT00312104
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa
Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 347
- Registration Number
- NCT00312156
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stirling, United Kingdom
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
Phase 3
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 746
- Registration Number
- NCT00294723
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 583
- Registration Number
- NCT00283751
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 79
- Registration Number
- NCT00282451
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 307
- Registration Number
- NCT00280046
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Voronezh, Russian Federation
Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00274274
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT00267683
Factor VIIa in Acute Intracerebral Haemorrhage
Phase 2
Completed
- Conditions
- Intracerebral HaemorrhageAcquired Bleeding Disorder
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 90
- Registration Number
- NCT00266006
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5652
- Registration Number
- NCT00264901
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath